COMBINATION OF XELODA, AND ANTICALMODULIN AND AN ANTI-P35 ANTIBODY FOR TRIPLE NEGATIVE BREAST CANCER.,
OR TAXOTERE-XELODA-VELCADE-ANTI-P35
If the fighting cancer strategy is to disrupt the cell where it hurts the most, the above combinations make the most sense. These combinations achieve the following:
1. Disruption of Microfilaments/Microtubules which in turn disrupt Anaphases in dividing cancer cells. This also disrupts membrane attachment of Cytochromes in Mitochondria by disrupting the Cytoskeleton, and leads to Caspase release.
2. Xeloda leads to an increase of intracellular 5-FU and to DNA breakage which triggers activation of P53 induced stoppage of cell division.
3. The Anti-Calmodulin will add and increase an intracellular release of Calcium leading to stimulation of Endonucleases which will further damage the DNA.
4. The Anti-P35 decreases resistance to Caspases since P35 is an inhibitor of Caspases.
5. To lead to growth advantage, most cancers get a mutation of the MDM2 which leads to increased ubiquitination proteins/cyclins favorable to apoptosis, making Velcade a powerful drug as it disrupts the proteasomes!
With these combinations, we are trying to harvest the strongest destructive forces in a cell!
A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
Showing posts with label anti-P35 antibody. Show all posts
Showing posts with label anti-P35 antibody. Show all posts
Wednesday, December 19, 2012
Subscribe to:
Posts (Atom)